Fourth Annual Chicago Supportive Oncology Conference

Volume 4, Number 12, Supplement 5 (December 2007)

Major Milestones in the Treatment of Indolent Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia
Improving Outcomes: Future Therapies

This activity is sponsored by the Elsevier Office of Continuing Medical Education and Excerpta Medica, Inc.

About this CME activity
Introduction and statement of needs • Accreditation statement • CME credit statement • Faculty disclosures • Unapproved/off-label use disclosure • Target audience • Program goals • Educational objectives • Financial support

full text 71 kb
Release date: December 7, 2007 • Expiration date: December 6, 2008

Contents

5

  

Current standards and future directions in treatment of follicular lymphoma

Brad Kahl, MD

Lymphoma Service, University of Wisconsin School of Medicine and Public Health, Madison, WI

abstract full text 255 kb

11

  

Chronic lymphocytic leukemia in 2007: prognostic factors and therapeutic approaches

Ayalew Tefferi, MD, and Susan O’Brien, MD

Department of Medicine, Mayo Clinic and Mayo School of Medicine, Rochester, MN, and Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX

abstract full text 318 kb

17

  

Self-assessment questions

full text 34 kb

19

  

CME answer sheet and evaluation form

full text 83 kb

This activity is supported by an educational grant from Cephalon, Inc.

© 2007 by Elsevier Inc. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the publisher.

The opinions expressed herein are those of the authors or advertisers. The authors, editors, and publishers make every effort to ensure that no inaccurate or misleading data, opinion, or statement is published in this journal and that drug names, dosages, and recommendations are accurate. However, readers should confirm all dosage schedules against the manufacturer’s package information data. The Publisher, Editorial Board, and their employees accept no liability whatsoever for the consequences of any inaccurate or misleading data, opinion, or statement.